Unlocking Q4 Potential of Albemarle (ALB): Exploring Wall Street Estimates for Key Metrics

07.02.25 15:15 Uhr

Werte in diesem Artikel
Aktien

74,47 EUR -1,48 EUR -1,95%

Indizes

1.854,4 PKT -8,4 PKT -0,45%

6.026,0 PKT -57,6 PKT -0,95%

The upcoming report from Albemarle (ALB) is expected to reveal quarterly loss of $0.41 per share, indicating a decline of 122.2% compared to the year-ago period. Analysts forecast revenues of $1.38 billion, representing a decrease of 41.6% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 18.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.With that in mind, let's delve into the average projections of some Albemarle metrics that are commonly tracked and projected by analysts on Wall Street.Analysts' assessment points toward 'Net Sales- Energy Storage' reaching $737.87 million. The estimate indicates a change of -56% from the prior-year quarter.The consensus among analysts is that 'Net Sales- Ketjen' will reach $300.11 million. The estimate indicates a change of -12.1% from the prior-year quarter.The consensus estimate for 'Net Sales- Specialties' stands at $341.79 million. The estimate indicates a change of +0.6% from the prior-year quarter.It is projected by analysts that the 'Adjusted EBITDA- Specialties' will reach $59.15 million. The estimate is in contrast to the year-ago figure of $29.84 million.View all Key Company Metrics for Albemarle here>>>Over the past month, shares of Albemarle have returned -9.6% versus the Zacks S&P 500 composite's +1.9% change. Currently, ALB carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Free Today: Profiting from The Future’s Brightest Energy SourceThe demand for electricity is growing exponentially. At the same time, we’re working to reduce our dependence on fossil fuels like oil and natural gas. Nuclear energy is an ideal replacement.Leaders from the US and 21 other countries recently committed to TRIPLING the world’s nuclear energy capacities. This aggressive transition could mean tremendous profits for nuclear-related stocks – and investors who get in on the action early enough.Our urgent report, Atomic Opportunity: Nuclear Energy's Comeback, explores the key players and technologies driving this opportunity, including 3 standout stocks poised to benefit the most.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Albemarle Corporation (ALB): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Albemarle

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Albemarle

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Albemarle Corp.

Wer­bung

Analysen zu Albemarle Corp.

DatumRatingAnalyst
16.11.2017Albemarle HoldDeutsche Bank AG
10.11.2017Albemarle OutperformRBC Capital Markets
09.11.2017Albemarle NeutralUBS AG
27.10.2017Albemarle OutperformBMO Capital Markets
25.09.2017Albemarle NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
10.11.2017Albemarle OutperformRBC Capital Markets
27.10.2017Albemarle OutperformBMO Capital Markets
08.05.2017Albemarle OutperformRBC Capital Markets
17.03.2017Albemarle OutperformRBC Capital Markets
01.03.2017Albemarle OutperformRBC Capital Markets
DatumRatingAnalyst
16.11.2017Albemarle HoldDeutsche Bank AG
09.11.2017Albemarle NeutralUBS AG
25.09.2017Albemarle NeutralRobert W. Baird & Co. Incorporated
10.03.2016Albemarle NeutralSeaport Global Securities
03.02.2015Albemarle Market PerformCowen and Company, LLC
DatumRatingAnalyst
16.08.2011Albemarle underperformOppenheimer & Co. Inc.
04.01.2006Update Albemarle Corp.: UnderweightJP Morgan

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Albemarle Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"